Malignant melanoma in HIV: Epidemiology, pathogenesis, and management.
HIV
immune checkpoint-based immunotherapy
malignant melanoma
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
18
11
2019
accepted:
23
11
2019
pubmed:
27
11
2019
medline:
25
11
2020
entrez:
27
11
2019
Statut:
ppublish
Résumé
People affected by immunodeficiency, and especially those infected by HIV, are burdened by a higher risk of developing malignancies. It has been estimated that the incidence of melanoma in HIV-infected people is 2.6-fold higher than in uninfected ones. In this group of patients, melanoma shows a more aggressive phenotype and poorer survival rates compared to HIV-negative people. Standard guidelines of diagnosis and care do not exist yet. Studies suggest high index of suspicion and a low threshold for biopsy in HIV-positive patients regardless of their CD4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13180Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
American Cancer Society. (2019, January 28). Key Statistics for Melanoma Skin Cancer. Retrieved from http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics
Andersson, T. M. L., Eriksson, H., Hansson, J., Månsson-Brahme, E., Dickman, P. W., Eloranta, S., … Lambert, P. C. (2014). Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. Cancer Epidemiology, 38(1), 93-99. http://doi.org/10.1016/j.canep.2013.12.006
Andreeva, V. A., & Cockburn, M. G. (2011). Cutaneous melanoma and other skin cancer screening among Hispanics in the United States: A review of the evidence, disparities, and need for expanding the intervention and research agendas. Archives of Dermatology, 147(6), 743-745. http://doi.org/10.1001/archdermatol.2011.140
Annessi, G., Bono, R., Sampogna, F., Faraggiana, T., & Abeni, D. (2007). Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: The importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. Journal of the American Academy of Dermatology, 56(5), 759-767. http://doi.org/10.1016/j.jaad.2007.01.014
Anzai, S., Anan, T., Kai, Y., Goto, M., Arakawa, S., Shimizu, F., … Fujiwara, S. (2005). Skin cancer screening on a fishing island and in an inland agricultural area of Japan. The Journal of Dermatology, 32(11), 875-882.
Argenziano, G., Puig, S., Zalaudek, I., Sera, F., Corona, R., Alsina, M., … Malvehy, J. (2006). Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. Journal of Clinical Oncology, 24(12), 1877-1882. http://doi.org/10.1200/JCO.2005.05.0864
Argenziano, G., Zalaudek, I., Hofmann-Wellenhof, R., Marchiori Bakos, R., Bergman, W., Blum, A., … Kittler, H. (2012). Total body skin examination for skin cancer screening in patients with focused symptoms. Journal of the American Academy of Dermatology, 66(2), 212-219. http://doi.org/10.1016/j.jaad.2010.12.039
Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., … Maio, M. (2017). Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial. The Lancet. Oncology, 18(5), 611-622. http://doi.org/10.1016/S1470-2045(17)30231-0
Associazione Italiana di Oncologia Medica. (2018, November 8). Linee guida MELANOMA. Retrieved from https://www.aiom.it/wp-content/uploads/2018/11/2018_LG_AIOM_Melanoma.pdf
Atteritano, M., Mirarchi, L., Venanzi Rullo, E., Santoro, D., Iaria, C., Catalano, A., … Cascio, A. (2018). Vitamin D status and the relationship with bone fragility fractures in HIV-infected patients: A case control study. International Journal of Molecular Sciences, 19(1), 119. http://doi.org/10.3390/ijms19010119
Augustin, M., Stadler, R., Reusch, M., Schäfer, I., Kornek, T., & Luger, T. (2012). Skin cancer screening in Germany-Perception by the public. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG, 10(1), 42-49. http://doi.org/10.1111/j.1610-0387.2011.07761.x
Baade, P., & Coory, M. (2005). Trends in melanoma mortality in Australia: 1950-2002 and their implications for melanoma control. Australian and New Zealand Journal of Public Health, 29(4), 383-386.
Baade, P., Meng, X., Youlden, D., Aitken, J., & Youl, P. (2012). Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006. International Journal of Cancer, 130(1), 170-178. http://doi.org/10.1002/ijc.25996
Badertscher, N., Meier, M., Rosemann, T., Braun, R., Cozzio, A., Tag, B., … Tandjung, R. (2014). The role of skin self-examination at the Swiss skin cancer day. BMC Health Services Research, 14(1), 581. http://doi.org/10.1186/s12913-014-0581-6
Bevelacqua, V., Bevelacqua, Y., Candido, S., Skarmoutsou, E., Amoroso, A., Guarneri, C., … Malaponte, G. (2012). Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget, 3(8), 879-889. http://doi.org/10.18632/oncotarget.594
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., & Picus, J. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 28(19):3167-3175.
Ceccarelli, M., Venanzi Rullo, E., Vaccaro, M., Facciolà, A., D'Aleo, F., Paolucci, I. A., … Guarneri, C. (2019). HIV-associated psoriasis: Epidemiology, pathogenesis, and management. Dermatologic Therapy, 75(10), e12806-e12806. http://doi.org/10.1111/dth.12806
Coghill, A. E., Shiels, M. S., Suneja, G., & Engels, E. A. (2015). Elevated cancer-specific mortality among HIV-infected patients in the United States. Journal of Clinical Oncology, 33(21), 2376-2383. http://doi.org/10.1200/JCO.2014.59.5967
Crum-Cianflone, N., Hullsiek, K. H., Satter, E., Marconi, V., Weintrob, A., Ganesan, A., … Agan, B. K. (2009). Cutaneous malignancies among HIV-infected persons. Archives of Internal Medicine, 169(12), 1130-1138. http://doi.org/10.1001/archinternmed.2009.104
D'Aleo, F., Venanzi Rullo, E., Ceccarelli, M., Facciolà, A., Condorelli, F., Pinzone, M. R., … Pellicanò, G. F. (2018). HIV and colorectal cancer. New insights and review of the literature. World Cancer Research Journal, 5(3), e1122.
D'Andrea, F., Ceccarelli, M., Venanzi Rullo, E., Facciolà, A., D'Aleo, F., Cacopardo, B., … Justice, A. (2018). Cancer screening in HIV-infected patients: Early diagnosis in a high-risk population. World Cancer Research Journal, 5(3), e1130.
Davar, D., Wilson, M., Pruckner, C., & Kirkwood, J. M. (2015). PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Reports in Oncological Medicine, 2015(4), 737389-737385. http://doi.org/10.1155/2015/737389
Facciolà, A., Ceccarelli, M., Venanzi Rullo, E., D'Aleo, F., Condorelli, F., Visalli, G., … Pellicanò, G. F. (2018). Prostate cancer in HIV-positive patients-A review of the literature. World Cancer Research Journal, 5(3), e1136.
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., … Bray, F. (2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359-E386. http://doi.org/10.1002/ijc.29210
Guarneri, C., Bevelacqua, V., Polesel, J., Falzone, L., Cannavò, P. S., Spandidos, D. A., … Libra, M. (2017). NF-κB inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma. Oncology Reports, 37(2), 737-746. http://doi.org/10.3892/or.2017.5362
Guarneri, C., Tchernev, G., Bevelacqua, V., Lotti, T., & Nunnari, G. (2016). The unwelcome trio: HIV plus cutaneous and visceral leishmaniasis. Dermatologic Therapy, 29(2), 88-91. http://doi.org/10.1111/dth.12303
Heppt, M. V., Schlaak, M., Eigentler, T. K., Kähler, K. C., Kiecker, F., Loquai, C., … Berking, C. (2017). Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Annals of Oncology, 28(12), 3104-3106. http://doi.org/10.1093/annonc/mdx538
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., … Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711-723. http://doi.org/10.1056/NEJMoa1003466
Le Garff, G., Samri, A., Lambert-Niclot, S., Even, S., Lavole, A., Cadranel, J., … Guihot, A. (2017). Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. Aids, 31(7), 1048-1051. http://doi.org/10.1097/QAD.0000000000001429
Maio, M., Grob, J.-J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., … Wolchok, J. D. (2015). Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Journal of Clinical Oncology, 33(10), 1191-1196. http://doi.org/10.1200/JCO.2014.56.6018
Marra, A., Scognamiglio, G., Peluso, I., Botti, G., Fusciello, C., Filippelli, A., … Sabbatino, F. (2017). Immune checkpoint inhibitors in melanoma and HIV infection. The Open AIDS Journal, 11(1), 91-100. http://doi.org/10.2174/1874613601711010091
National Comprehensive Cancer Network. (2017, December 19). NCCN guidelines for patients: Melanoma. Retrieved from https://www.nccn.org/patients/guidelines/melanoma/files/assets/common/downloads/files/melanoma.pdf
Olsen, C. M., Knight, L. L., & Green, A. C. (2014). Risk of melanoma in people with HIV/AIDS in the pre- and post-HAART eras: A systematic review and meta-analysis of cohort studies. PLoS One, 9(4), e95096. http://doi.org/10.1371/journal.pone.0095096
Pinzone, M. R., Ceccarelli, M., Venanzi Rullo, E., Maresca, M., Bruno, R., Condorelli, F., … Pellicanò, G. F. (2019). Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. Biomedical Reports, 10(2), 140-144. http://doi.org/10.3892/br.2019.1183
Pinzone, M. R., VanBelzen, D. J., Weissman, S., Bertuccio, M. P., Cannon, L., Venanzi Rullo, E., … O'Doherty, U. (2019). Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nature Communications, 10(1), 728. http://doi.org/10.1038/s41467-019-08431-7
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015). Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology, 33(17), 1974-1982. http://doi.org/10.1200/JCO.2014.59.4358
Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Koo, C., Park, J. J., … Menzies, A. M. (2017). 1148PD: Immunotherapy in patients with concurrent solid organ transplant, HIV, and hepatitis B and C. Annals of Oncology, 28(Suppl._5), 408. http://doi.org/10.1093/annonc/mdx376.013
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., … Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364(26), 2517-2526. http://doi.org/10.1056/NEJMoa1104621
Rodrigues, L. K. E., Klencke, B. J., Vin-Christian, K., Berger, T. G., Crawford, R. I., Miller, J. R., … Kashani-Sabet, M. (2002). Altered clinical course of malignant melanoma in HIV-positive patients. Archives of Dermatology, 138(6), 765-770.
Russo, A., Ficili, B., Candido, S., Pezzino, F. M., Guarneri, C., Biondi, A., … Libra, M. (2014). Emerging targeted therapies for melanoma treatment (review). International Journal of Oncology, 45(2), 516-524. http://doi.org/10.3892/ijo.2014.2481
Ryška, A., Horký, O., Berkovcová, J., Tichá, I., Kalinová, M., Matějčková, M., … Vošmiková, H. (2017). Malignant melanoma-From classical histology towards molecular genetic testing. Klinicka Onkologie: Casopis Ceske a Slovenske Onkologicke Spolecnosti, 30(3), 182-189. http://doi.org/10.14735/amko2017182
Shannan, B., Perego, M., Somasundaram, R., Herlyn, M., Berwick, M., & Buller, D. B. (2016). In H. L. Kaufman & J. M. Mehnert (Eds.), Cancer treatment and research (Vol. 167, 1st ed.). Switzerland: Springer International Publishing. http://doi.org/10.1007/978-3-319-22539-5
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(1), 7-34. http://doi.org/10.3322/caac.21551
Skarmoutsou, E., Bevelacqua, V., D'Amico, F., Russo, A., Spandidos, D. A., Scalisi, A., … Guarneri, C. (2018). FOXP3 expression is modulated by TGF-β1/NOTCH1 pathway in human melanoma. International Journal of Molecular Medicine, 42(1), 392-404. http://doi.org/10.3892/ijmm.2018.3618
Streeck, H., & Nixon, D. F. (2010). T cell immunity in acute HIV-1 infection. Journal of Infectious Diseases, 202(Suppl. 2), S302-S308. http://doi.org/10.1086/655652
Swetter, S. M., Tsao, H., Bichakjian, C. K., Curiel-Lewandrowski, C., Elder, D. E., Gershenwald, J. E., … Lamina, T. (2019). Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 80(1):208-250. http://doi.org/10.1016/j.jaad.2018.08.055
Tomsitz, D., Hein, R., Biedermann, T., & Kohlmeyer, J. (2018). Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab. Journal of the European Academy of Dermatology and Venereology: JEADV, 32(1), e26-e28. http://doi.org/10.1111/jdv.14450
Venanzi Rullo, E., Ceccarelli, M., Condorelli, F., Facciolà, A., Visalli, G., D'Aleo, F., … Pellicanò, G. F. (2019). Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (review). Molecular Medicine Reports, 19(3), 1987-1995. http://doi.org/10.3892/mmr.2019.9840
Wernli, K. J., Henrikson, N. B., Morrison, C. C., Nguyen, M., Pocobelli, G., & Blasi, P. R. (2016). Screening for skin cancer in adults: Updated evidence report and systematic review for the US preventive services task force. JAMA, 316(4), 436-447. http://doi.org/10.1001/jama.2016.5415
Wilkins, K., Dolev, J. C., Turner, R., LeBoit, P. E., Berger, T. G., & Maurer, T. A. (2005). Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatologic Therapy, 18(1), 77-86. http://doi.org/10.1111/j.1529-8019.2005.05003.x
Zhang, D., Dong, Y., Sun, X., Yuan, S., & Yu, J. (2019). Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: A population-based, propensity-matched study. Cancer Management and Research, 11, 339-346. http://doi.org/10.2147/CMAR.S187208